drugset

drugset / Trial / NCT01284595

Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931

NCT01284595 ↗

Phase 1 Completed 6 enrolled AstraZeneca

NaSingle-groupOpen-label

Summary

Study to Assess the Absorption, Metabolism and Excretion of \[14C\]AZD8931 after a Single-Dose Oral Administration

Timeline

Start: 2011-03
Primary completion: 2011-05
Completion: 2011-05

Publications

Ballard P, Swaisland HC, Malone MD, Sarda S, Ghiorghiu S, Wilbraham D. Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. Xenobiotica. 2014 Dec;44(12):1083-98. doi: 10.3109/00498254.2014.938257. Epub 2014 Jul 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAPITINIB	Small molecule	160 mg	Oral

Indications

No indication recorded.